Geneva, Feb. 13 -- International Clinical Trials Registry received information related to the study (ChiCTR2600118350) titled 'A clinical application study on thymalfasin-regulated hypofractionated radiotherapy combined with adebrelimab in hepatocellular carcinoma after PD-1 therapy resistance' on Feb. 4.
Study Type: Interventional study
Study Design:
Single arm
Primary Sponsor: Chuzhou First People's Hospital
Condition:
Liver cancer
Recruitment Status: Not Recruiting
Phase: N/A
Date of First Enrollment: 2026-02-09
Target Sample Size: Immunotherapy group:12;
Countries of Recruitment:
China
To know more, visit https://www.chictr.org.cn/showproj.html?proj=308037
Published by HT Digital Content Services with permission from ...